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Cost-effectiveness analysis of natriuretic peptide testing and specialist outreach in patients with 1 
suspected acute heart failure 2 
ABSTRACT 3 
Aims 4 
To determine the cost-effectiveness of natriuretic peptide (NP) testing and specialist outreach in acute 5 
heart failure patients residing off the cardiology ward.  6 
Methods 7 
We used a Markov model to estimate costs and quality-adjusted life years (QALYs) for patients 8 
presenting to hospital with suspected acute heart failure (AHF). We examined diagnostic work-up with 9 
and without the NP test in suspected new cases; and we examined the impact of specialist heart 10 
failure outreach in all suspected cases. Inputs for the model were derived from systematic reviews, 11 
the UK national heart failure audit, RCTs, expert consensus from a NICE guideline development 12 
group, and a national online survey. The main benefit from specialist care (cardiology ward and 13 
specialist outreach) was the increased likelihood of discharge on disease modifying drugs for people 14 
with left ventricular systolic dysfunction, which improve mortality and reduce readmissions due to 15 
worsened heart failure (associated with lower utility). Costs included diagnostic investigations, 16 
admissions, pharmacological therapy, and follow-up heart failure care. 17 
Results 18 
NP testing and specialist outreach are both higher cost, higher QALY, cost effective strategies (ICERs 19 
of £11,656 and £2,883 per QALY gained, respectively). Combining NP and specialist outreach is the 20 
most cost effective strategy. This result was robust to both univariate deterministic and probabilistic 21 
sensitivity analyses. 22 
Conclusions 23 
NP testing for the diagnostic work-up of new suspected AHF is cost effective. The use of specialist 24 
heart failure outreach for AHF inpatients residing off the cardiology ward is cost effective. Both 25 
interventions will help improve outcomes for this high risk group.  26 
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INTRODUCTION 1 
A diagnosis of acute heart failure (AHF) is challenging and is confirmed in only 40-50% of suspected 2 
cases.1 Symptoms and signs are often non-specific and may overlap with a number of alternative 3 
diagnoses. Mortality in patients following a period of hospitalisation for heart failure is high at 25% 4 
over one year,2 so it is important to examine where changes to diagnosis and treatment strategies 5 
might lead to improvement. The measurement of plasma natriuretic peptide (NP) levels has been 6 
recommended in international guidelines for the diagnosis of heart failure with the aim of excluding the 7 
diagnosis of heart failure at an early stage to allow targeted, clinically appropriate and resource 8 
efficient investigation.3, 4 However adoption of NP in acute care settings in some countries (e.g. the 9 
UK) has been limited, in part due to the additional costs but also uncertainty in the incremental benefit 10 
and cost effectiveness. While economic evaluations suggest NP testing is cost effective in the acute 11 
setting,5-8 these did not examine its impact on health-related quality of life (HRQoL), a preferred 12 
measure of benefit for inclusion in economic evaluation.9 Management of patients hospitalised with 13 
acute heart failure by specialist multi-disciplinary teams is associated with reduced in-hospital 14 
mortality and an increase in use of proven medical therapies.2 Currently there is significant regional 15 
variation in the degree of specialist involvement in in-hospital management of heart failure.2, 10 We are 16 
not aware of any previous cost effectiveness analysis of specialist care arrangements for AHF. 17 
This combined evaluation was conducted as part of the National Institute for Health and Care 18 
Excellence (NICE) guideline on diagnosing and managing AHF (CG187).11 In a diagnostic analysis 19 
we report the cost effectiveness of the NP test for the diagnostic work-up of suspected new AHF 20 
cases compared to standard clinical investigations (physical examination, electrocardiography, chest 21 
radiography, and routine blood tests). And in an analysis of care management in all suspected cases, 22 
we report the cost effectiveness of specialist heart failure outreach compared to no outreach in a 23 
multi-ward arrangement typical of many hospitals in the UK and elsewhere. 24 
METHODS 25 
Modelling approach and structure 26 
We conducted a cost-utility analysis in Microsoft® Excel 2010 to determine the cost-effectiveness of 27 
NP in a diagnostic analysis, and specialist outreach in a care management analysis. Four strategies 28 
combined the two analyses:  29 
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 Standard clinical investigations, and no specialist outreach 1 
 NP test and no specialist outreach 2 
 Standard clinical investigations, and specialist outreach 3 
 NP test and specialist outreach 4 
Base case costs, life-years, and quality-adjusted life years (QALYs) are calculated over a time-5 
horizon of four years. This was the available follow-up period for patients included in the national 6 
heart failure audit at the time of analysis, and was accepted by expert clinical consensus as long 7 
enough to capture most important differences in costs or outcomes between strategies. The 8 
evaluation perspective is that of the health system payer of England and Wales, costs are reported in 9 
2013 GBP, and future costs and benefits are discounted at 3.5% per year.12 The modelled population 10 
is patients suspected of AHF presenting to the emergency department with dyspnoea and no clear 11 
alternative diagnosis. Inputs for the analyses have been obtained from a range of sources, and where 12 
required we selected the most conservative of available alternatives i.e. least favourable to NP and 13 
specialist outreach. Table 1 summarises key assumptions and presents the input parameters used in 14 
the base case. 15 
The model structure is a decision tree into a Markov chain. The decision tree (Figure 1) deals with 16 
differences in true condition within the starting population, the diagnostic work-up, and the subsequent 17 
nature of care. The starting cohort proceed firstly through two epidemiological chance nodes to sort 18 
by true underlying disease and underlying cause. Two further chance nodes then divide by outcome 19 
of diagnostic work-up, and in the case of false negatives, the likelihood of identification and corrective 20 
action. The care management strategies are then conceived by a division into those who receive 21 
specialist care (by virtue of residing on a cardiology ward, or involvement of an outreach team), and 22 
those who receive standard care. The resultant subgroups are passed into a subsequent Markov 23 
chain with three-month transition cycles (Figure 2). A survival analysis informs the probability of death 24 
within each cycle, given the patients true condition, cause, diagnostic work-up and subsequent care. 25 
Patients remaining alive are in chronic heart failure (CHF) and are at risk-of readmission from 26 
worsening of their condition. 27 
Work-up diagnosis 28 
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The starting cohort are 47% true for AHF and 65% true for left ventricular systolic dysfunction (LVSD) 1 
as the predominant underlying cause.13, 14 Fifty-six per cent are male, for whom the entry age is 75 2 
years, and women enter at 80 years, reflecting the typical ages of people presenting with AHF in the 3 
UK.2 The sensitivity and specificity of work-up diagnosis using standard clinical investigations is 4 
extracted from the physician only receiver operating characteristic (ROC) curve (apex) of the 5 
Breathing Not Properly multi-national study. The accuracy of the NP test is drawn from a systematic 6 
review and meta-analysis using recognised cut-offs (100 ng/L for B type natriuretic peptide and 300 7 
ng/L for NTproBNP).13,15 Eighty per cent of false negative work-ups are corrected during admission 8 
(expert consensus) resulting in a short non-detrimental delay in discharge. The remaining twenty per 9 
cent have an increase in risk of death and readmission equal to untreated LVSD, plus two additional 10 
days of hospitalisation. Patients with a false positive work-up receive echocardiography so are 11 
presumed to be identified early. 12 
Care management 13 
Patients can either receive care which includes specialist heart failure input or receive standard care, 14 
in which there is no heart failure specialist involvement during acute admission. Negative work-ups in 15 
all strategies receive standard care on general medical wards. Positive work-ups in all strategies are 16 
divided into half who receive standard care on general medical wards and half who receive specialist 17 
care on cardiology wards, as is the national picture.2 However, in specialist outreach strategies, 18 
patients residing on general wards receive additional heart failure specialist care from an outreach 19 
team, and are attributed the same health benefits from specialist care as received by patients residing 20 
on cardiology wards. In respect to resource use, 20% of patients on cardiology wards also receive 21 
input from a non-cardiologist (expert consensus). 22 
Benefit of specialist care 23 
There is good evidence that ACE inhibitors, angiotensin receptor blockers, beta blockers, and 24 
aldosterone antagonists/ mineralocorticoid receptor antagonists improve outcomes for people with 25 
heart failure due to LVSD.16, 17 Therefore we attribute reduced mortality and risk of readmission to 26 
AHF patients with LVSD, following discharge, according to the likelihood being discharged with these 27 
drugs. The proportion of people receiving these interventions, according to whether or not a specialist 28 
nurse or physician was involved in acute care, is based on a secondary analysis of the most recent 29 
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year of data from the national heart failure audit which adjusted for potential confounders using 1 
logistic regression propensity modelling (Table 1).14  2 
Four year survival and readmission curves were plotted (Figure 3) using hazard ratios (Table 2) 3 
applied to baseline rates sourced directly from the national audit (supplementary material B Figure 8). 4 
For the ten-year scenario analysis, subsequent years were based on a Weibull parametric 5 
extrapolation (supplementary material A Figure S1). Cardiovascular mortality baseline risk is based 6 
on those who survived beyond discharge with no recorded discharge HF medication.14 The baseline 7 
risk of readmission due to worsened heart failure is based on a study of UK CHF patients who 8 
received minimal treatment relative to current recommendations.18 Hazard ratios are calculated from 9 
risk ratios produced from meta-analyses of drug effect sizes from RCTs identified in a pre-specified 10 
search protocol (Table 2. Also see supplementary material A Figure S2 for meta-analysis forest plots). 11 
In the absence of suitable systematic reviews, we pooled together the results of large (n≥1,000) 12 
placebo controlled RCTs of ACEi/ARAs, BBs and MRAs in a chronic LVSD population, which reported 13 
cardiovascular mortality. We excluded trials that focused on an acute MI population. 14 
In addition to benefits based on prescribing patterns we apply a lower in-hospital mortality at 15 days 15 
for patients receiving specialist management, based on a confounder adjusted analysis of patients 16 
with LVSD from the national audit (supplementary material B, Figures 3 and 5).14 Conservatively, we 17 
have not attributed any health benefit from specialist care to patients who did not have LVSD, whilst 18 
including these populations in the cost summation. 19 
Health-related quality of life 20 
The HRQoL of patients who are stable post-discharge (CHF health state) is calculated using the 21 
NYHA functional class utilities taken from a sample of UK heart failure patients.19 A single weighted 22 
average is derived according to the class distribution observed in a representative UK cohort.20 To 23 
account for worsened heart failure associated with hospital admission, a utility decrement is applied 24 
over a six week period around readmissions, including the index admission. This is calculated from 25 
EQ-5D data collected in the Systolic Heart failure treatment with the lf inhibitor ivabradine Trial (SHIfT, 26 
unpublished data provided by Servier Laboratories Ltd, 2014). 27 
Costs 28 
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Utilised resources include the NP test (where strategized, £28.13), echocardiograms (indicated 1 
whenever a diagnosis of new AHF is sought), staffing of hospital teams, occupancy of inpatient beds, 2 
and follow-up community based care. The time requirement of a specialist heart failure outreach 3 
team, comprising a specialist consultant physician and a heart failure specialist nurse, is based on our 4 
online survey of role-based patient-related activity by ward setting in acute providers of England and 5 
Wales. Standard sources inform unit costs of staffing, which include the cost of specialist training.21 6 
The cost of the average inpatient bed stay is calculated using the NHS daily cost of bed occupancy 7 
weighted for complication rate, and the national median length of stay for episodes of AHF.2, 22 Follow-8 
on costs accrued in CHF include LVSD drug acquisition, hospital outpatient visits, GP visits, and 9 
community specialist nurse. The probability of being successfully referred to follow-on services is 10 
increased if specialist care was received.2 Expert opinion has been elicited to inform the intensity of 11 
health system contacts. 12 
Analysis 13 
The model was run both deterministically (i.e. based on the point estimates of all input parameters) 14 
and probabilistically (i.e. based on a distribution for each input). The main results are based on the 15 
probabilistic analysis, which allowed the calculation of 95% confidence intervals. Distributions were 16 
defined according to the nature of the data (for example hazard ratios are lognormally distributed) and 17 
parameterised using standard error estimates from data sources, or where absent, were set to equal 18 
the mean divided by four. Incremental findings were recomputed after each simulation and appeared 19 
to have become stable by the 1,000th simulation. We also tested the robustness of the model by 20 
individually varying potentially sensitive model inputs in the deterministic analysis by 10%, and we 21 
tested pre-selected structural uncertainty by applying plausible alternatives using literature sources or 22 
expert clinical opinion.  The incremental cost effectiveness ratio (ICER) was used for pair-wise 23 
strategy comparison and the net monetary benefit (NMB) for comparison across all four strategies. 24 
For a particular cost-effectiveness threshold the NMB is calculated by multiplying the total QALYs for 25 
a comparator by the threshold cost per QALY and then subtracting the total strategy cost. The 26 
comparator with the highest NMB is the most cost-effective option at the specified threshold because 27 
it provides the highest number of QALYs at an acceptable cost. 28 
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RESULTS 1 
Diagnostic outcomes 2 
The higher sensitivity and lower specificity of work-up diagnosis using the NP test, compared to 3 
standard clinical investigations, results in fewer false negatives (2.3% versus 9.4%) and more 4 
frequent false positive work-ups (19.8% versus 12.2%). A consequence of this is an increased 5 
demand for echocardiography (668 versus 592 echocardiograms per 1,000 patients). A detailed 6 
breakdown of the diagnostic accuracy can be found in supplementary material A Table S1. 7 
Health outcomes 8 
Survival curves for patients with LVSD and non-LVSD AHF are shown in Figure 3. Patients with LVSD 9 
who have an incorrect work-up at the index admission have the poorest survival (30% alive at 4-10 
years). Patients receiving care from a specialist have a higher likelihood of survival than those who do 11 
not (36% alive at 4-years versus 31%). They also have a lower probability of worsened heart failure 12 
and consequent readmission. Overall the NP test and specialist outreach increase the average health 13 
of the modelled population in terms of increased life-years as well as QALYs gained (Table 3). 14 
Optimal QALY gain is achieved in the strategy combining the NP test and specialist outreach.  15 
Costs  16 
Strategies utilising the NP test have higher diagnostic work-up costs, index admission costs, drug 17 
acquisition and follow-up care costs than non-NP strategies; but costs arising from readmission are 18 
lower (Table 3). Similarly, specialist outreach strategies are more costly in the short-run but are 19 
effective in reducing long-term costs. Over four years the individual cost of NP testing and specialist 20 
outreach is higher than standard strategies, but the difference is small at the individual patient level. 21 
The impact on the cost and time-requirement of staff can be found in supplementary material A Table 22 
S2. 23 
Cost effectiveness 24 
NP testing was cost effective versus no test, with an ICER of £11,656 per QALY gained [95% CI: 25 
£4,641, £23,774], and specialist outreach was cost effective compared to no outreach, the ICER 26 
£2,883 per QALY gained [95% CI: £2,103, £4,324]. Combining these two strategies was cost 27 
effective, the ICER £4,350 per QALY gained [95% CI: £2,976, £6,788]. Introducing NP testing where 28 
specialist outreach already exists is also cost effective, the ICER £7,914 per QALY gained [95% CI: 29 
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£4,007, £14,554]. The combination of specialist outreach with NP testing was convincingly cost 1 
effective, being the most cost effective of all strategies in more than 99% of the probabilistic 2 
simulations. Univariate sensitivity analysis found specialist outreach to be cost effective compared to 3 
no outreach in all tests. NP testing was cost effective in all tests except in a scenario where in-hospital 4 
mortality benefit linked to specialist involvement is nullified and specialist outreach is not offered (see 5 
supplementary material A Table S3 for results of all sensitivity analyses).  6 
DISCUSSION 7 
We have conducted a cost utility analysis in order to estimate costs and QALYs associated with the 8 
diagnosis and management of suspected AHF in patients presenting to an acute hospital with 9 
dyspnoea. Individually, strategies of NP testing and specialist outreach were more costly but also 10 
more cost effective than standard investigations and standard management respectively. The 11 
combined strategy of NP testing and specialist outreach was a cost effective strategy (£7,914 per 12 
QALY gained) but also the optimum strategy in terms of net monetary benefit. The adoption of the 13 
combined strategy in acute care settings has the potential to improve morbidity and mortality in a 14 
group of patients who have a high risk of readmission and mortality following an acute hospital 15 
admission.  16 
There have been no previous evaluations of the cost effectiveness of arrangements of specialist care 17 
for AHF, at the time of writing this is the first evaluation of specialist outreach. However, there are 18 
previous European and US cost effectiveness analyses of NP in AHF. These have found that NP 19 
testing produces a net saving whereas we have found there is a marginal increase in overall cost.5-8 If 20 
we test higher sensitivity and lower specificity in work-up using standard investigations then we too 21 
find a cost saving from fewer false negative cases, but we expect clinicians in this situation to 22 
maximise specificity in order to increase the certainty of ruling-out AHF. 23 
Where possible we have made conservative choices around structural aspects of model design in the 24 
management analysis: no benefit from specialist care is given to patients with non-LVSD heart failure 25 
even though the cost of the additional specialist time was included; specialist care attracts additional 26 
outpatient and community costs; and we exclude potential benefits associated with specialist care 27 
such as those from cost-effective implantation of devices.11 Also, the selected time horizon is shown 28 
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to be conservatively short since extrapolation of the survival analysis to ten years reveals uncaptured 1 
low cost QALYs beyond four years. However, the pivotal evidence informing effect size in the 2 
management analysis – although the most contemporary and relevant - is non-randomised. Our 3 
literature review did identify two cohort studies as alternative sources of resource-related mortality. 4 
Auerbach et al prospectively examined costs and clinical outcomes of patients admitted with 5 
congestive heart failure cared for by cardiologists, versus patients cared for by generalists in five US 6 
hospitals between 1989 and 1994 (n=1,298).4 Cardiologist care was associated with greater costs 7 
and resource use and no difference in survival at 30 days of follow-up. Lowe et al (2000) conducted a 8 
similar smaller study in a single hospital in Australia (n=275).23 The use of cardiac drugs and 9 
investigations was similar in the two groups; the generalists' patients had a longer length of hospital 10 
stay; and the cardiologists' patients had a higher mortality during the early follow-up period. The 11 
authors noted confounding in that patients under the generalist were older, had greater co-morbidity, 12 
but appeared to have less severe cardiac disease than those under the cardiologist. Therefore these 13 
cohort studies are open to the same sources of confounding as the unadjusted national audit, but are 14 
less applicable to current heart failure care in the modelled setting. The 2012/13 UK national heart 15 
failure audit is approximately a 60% sample, included returns from 145 NHS Trusts and Health 16 
Boards in Wales (97%) and included 43,894 heart failure coded discharges or deaths. To tackle 17 
inevitable confounding in the key statistic we used logistic regression to calculate the propensity of a 18 
hospitalised AHF patient being prescribed LVSD drugs according to whether or not the care received 19 
included input from a specialist, adjusting for 13 potentially confounding covariates including NYHA 20 
class. It is conceivable that there is residual confounding that could result in an over-estimation of the 21 
impact of specialist care but our conservative assumptions will diminish this effect. Going further, 22 
even if the mortality benefit of specialist input over the period of admission is excluded, a strategy of 23 
specialist outreach remains cost effective compared to standard care in which there is no outreach. 24 
 25 
In the diagnostic analysis we can have some confidence in the parameters informing the accuracy of 26 
the NP test, since the estimate is from a meta-analysis of 37 unique study cohorts.15 However the 27 
estimate of accuracy of emergency department physician work-up using standard clinical 28 
investigations is derived from the ROC curve of a single trial.13 Although in sensitivity testing using 29 
alternative plausible estimates the result was unchanged.15 But important to the context of our finding, 30 
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sensitivity and specifically estimates for approaches are based on populations of suspected AHF 1 
which include previously known cases. Therefore in our analysis of suspected new cases the model 2 
may potentially over-estimate the cost effectiveness of NP, since the proportion of true cases 3 
amongst new ones would be relatively lower and therefore the number detected will be smaller as a 4 
proportion of the whole. Equally the test’s cost effectiveness may be under-estimated because the 5 
ability of the physician using standard investigations to accurately identify true cases amongst only 6 
new cases is likely to be poorer. Also because when applied in clinical practice, physicians may 7 
choose to use the NP test more selectively where there is diagnostic uncertainty, rather than in every 8 
new patient. Finally, we assume no health loss for false positives, which are more frequent with the 9 
test. To do so may reduce cost effectiveness but given that positive work-ups typically proceed to 10 
echocardiography in clinical practice any negative health impact will be limited.   11 
Conclusion 12 
Natriuretic peptide testing of suspected new cases of AHF, and the adoption of specialist outreach 13 
teams for those patients residing off the cardiology ward, may improve outcomes for patients with 14 
AHF in a cost effective manner. Adoption of these approaches in similar health care systems may 15 
provide further incremental benefit to the outcomes of patients presenting acutely with heart failure.  16 
 17 
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Figure 1 
 
 
 
Figure 1. The decision tree of the diagnostic analysis 
Abbreviations: AHF = Acute heart failure; LVSD = Left ventricular systolic disfunction. 
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Figure 2 
 
 
 
 
Figure 2. Schematic diagram of Markov model. (A) Patients heart failure, (B) Patients with other 
conditions. 
States of the model are represented by ovals and allowed transitions between states are represented 
by arrows. Circular arrows indicate that patients may remain in the state for consecutive cycles. 
Quality of life weights (or utilities, u) and costs (c) are specific for each health state. Patients who are 
not alive do not accrue costs and have zero utility. The cost of AHF is different according to whether 
suspected (cAHFindex) or worsened leading to readmission (cAHFreadm). 
Abbreviations: AHF = Acute Heart Failure; CHF = Chronic heart failure; UH = Usual health.  
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Figure 3 
 
 
Figure 3.  Four year survival curve for patients admitted with acute heart failure 
Abbreviations: FN = False negative (work-up); LVSD = Left ventricular systolic dysfunction; TP = True 
positive (work-up). 
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TABLES 
Table 1 Summary of assumptions and inputs used in the base case model 
Assumption Impact Applied  population and 
period  
A false positive initial work-up is not harmful since it 
will be followed-up with an early echocardiogram 
None All false positive patients 
A false negative initial work-up prolongs 
hospitalisation 
2 days extra in hospital All false negative patients; 
applied to the index 
admission only 
A prolonged misdiagnosis of AHF reduces survival No treatment and benefit from 
ACEi/ARA, BB or MRA  
All false negatives with 
LVSD which are not 
corrected during index 
admission; 3 months only 
A prolonged misdiagnosis of AHF increases risk of 
readmission 
Risk of readmission increases to 1/3  
Input parameter description 
Point 
estimate 
Distribution parameters 
used in probabilistic 
analysis Source 
Diagnosis parameters – Beta distributions 
Prevalence of AHF in patients presenting to emergency 
department with acute dyspnoea suspected of AHF 
47% α = 722, β = 864 Breathing Not Properly 
multinational study13 
Prevalence of LVSD in patients with true underlying 
AHF 
65% α = 18628, β = 10030 Secondary analysis of the 
National Heart Failure 
Audits of England and 
Wales 2009-2013 (from 
2012/13 data) 14 
Sensitivity of working diagnosis without NP test  80% α = 578, β = 144 Breathing Not Properly 
multinational study13 
(Thresholds of 100 ng/L for 
B type natriuretic peptide 
and 300 ng/L for NTproBNP) 
Specificity of working diagnosis without NP test  77% α = 556, β = 166 
Sensitivity of working diagnosis with BNP test 95.1% α = 3560590, β = 
182278 
Systematic review and 
diagnostic meta-analysis in 
the acute care setting15 Specificity of working diagnosis with BNP test 62.7% α = 299152, β = 177813 
Probability of correction of a false work-up in a patient 
with AHF 
80% α = 2.4, β = 0.6 Consensus of expert clinical 
opinion 
Baseline mortality – Beta distributions 
In-hospital mortality with specialist input: LVSD 3.3% α = 372, β = 10905 Secondary analysis of the 
National Heart Failure 
Audits of England and 
Wales 2009-201314 
In-hospital mortality: Non-LVSD 5.3% α = 205, β = 3667 
In-hospital mortality without specialist input: LVSD 6.3% N/a Calculated 
Annual all-cause mortality in age and gender adjusted 
population 
4.6% N/a National heart failure audit 
2012/13,2 and Office for 
National Statistics24, 25 
Ratio of CV to all-cause deaths 0.796 α = 1253, β = 321 ELITE II study26 
Ratio of heart failure to all-cause readmissions 0.459 α = 294, β = 495 
Treatment effect – LogNormal distributions 
Hazard ratio in-hospital mortality, Specialist vs no 
specialist: LVSD 
1.94 se(LnHR) = 0.09 Secondary analysis of the 
National Heart Failure 
Audits of England and 
Wales 2009-2013  (from 
2012/13 data14  
Hazard ratio in-hospital mortality, Specialist vs no 
specialist: Non-LVSD 
1.95 se(LnHR) = 0.11 
Hazard ratio post-discharge CV mort ACEi/ARA vs 
placebo 
0.898 se(LnHR) = 0.04 CHARM(LLEF),27 Val-HEFT,28 
SOLVD-T29 
Risk ratio post-discharge HF readm ACEi/ARA vs 
placebo 
0.800 se(LnHR) = 0.03 
Hazard ratio post-discharge CV mortality BB vs placebo 0.738 se(LnHR) = 0.12 BEST,3 CIBIS-2,30 MERIT-HF31 
Risk ratio post-discharge HF readmission BB vs placebo 0.760 se(LnHR) = 0.06 BEST,3 CIBIS-2,30 
COPERNICUS32 
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Hazard ratio post-discharge CV mort MRA vs placebo 0.788 se(LnHR) = 0.04 EMPHASIS33 
Risk ratio post-discharge HF readm MRA vs placebo 0.650 se(LnHR) = 0.02 
Treatment effect – Beta distributions 
Probability of ACEi or ARB treatment: Specialist team 78% α =4285 , β = 1208 Secondary analysis of the 
National Heart Failure 
Audits of England and 
Wales 2009-2013 (from 
2012/13 data)*14  
Probability of ACEi or ARB treatment: General medical 
team 
61% α = 887, β = 575 
Probability of BB treatment: Specialist input 87% α = 4676, β = 723 
Probability of BB treatment: No specialist input 59% α = 840, β = 593 
Probability of MRA treatment: Specialist input 38% α = 2042, β = 3345 
Probability of MRA treatment: No specialist input 18% α = 258, β = 1186 
Resource parameters – Gamma distributions 
Mins/pt/week Cardiologist on a cardiology ward 20 se = 2.92  Online survey conducted by 
the National Institute for 
Cardiology Outcomes 
Research (NICOR), 
November 2013 
(unpublished) 
Mins/pt/week Cardiologist on a non-cardiology ward 20 se = 2.8 
Mins/pt/week Non-cardiologist on a cardiology ward 15 se = 4.15 
Mins/pt/week Non-cardiologist on a non-card ward 23 se = 2.68 
Mins/pt/week HFSN on a cardiology ward 30 se = 7.53 
Mins/pt/week HFSN on a non-card ward 30 se = 7.06 
Proportion of cardiology ward patients seen by a non-
cardiologist 
0.2 se = 0.05 Consensus of expert clinical 
opinion 
Median length of index stay (days) 8.0 se = 2 National heart failure audit 
2012/132 
Length of stay penalty for false working diagnoses 
(days applied to initial stay, only) 
2.0 se = 0.5 Consensus of expert clinical 
opinion 
Other Resource inputs 
Prob. outpatient f/up when care from cardiology ward 71% N/a National heart failure audit 
2012/132 Prob. community f/up when care from cardiology ward 68% N/a 
Prob. outpatient f/up when care from non-card ward 22% N/a 
Prob. community f/up when care from non-card ward 23% N/a 
Prob. outpatient f/up when care by outreach team 50% N/a 
Prob. community f/up when care by outreach team 71% N/a 
Cardiology outpatient follow-ups in first year 2 N/a Consensus of expert clinical 
opinion Cardiology outpatient follow-ups in subsequent years 1 N/a 
Community HFSN follow-ups per annum 4 N/a 
Annual GP visits when without community support 7 N/a 
Annual GP visits when receiving community support 3 N/a 
Unit cost parameters (£) – Gamma distributions 
Echocardiogram 63.60 se = 15.65 NHS Reference costs 
schedule 2012-13 Bed day 232.09 se = 58.02 
Natriuretic peptide test (BNP) 28.13 se = 7.03 Personal correspondence, 
St Georges Healthcare NHS 
Trust 
Consultant hour (Cardiologist/General Physician) 132 se = 33.00 Personal Social Services 
Research Unit Handbook 
201321 
HFSN hour 52 se = 13.00 
GP visit 37 N/a 
Community HFSN visit 42 N/a 
Hospital outpatient visit 131 N/a NHS Reference costs 
schedule 2012-1321 
ACE inhibitor/Angiotensin receptor antagonist (day) 0.11 N/a Prescription cost analysis 
England 201210 Beta blocker (day) 0.07 N/a 
Mineralocorticoid receptor antagonist (day) 0.20 N/a 
Dis-utility parameters – Gamma distribution 
Dis-utility for 3-months in AHF 0.064 se = 0.016 Unpublished data from the 
SHIfT trial, supplied by 
Servier Laboratories Ltd 
Utility parameters – Beta distribution 
Chronic heart failure 0.752 α = 966, β = 318 BATTLESCARRED trial,20 and 
health technology 
assessment19 
Usual health (non-heart failure) 0.752 N/a 
Suspected acute/Worsened heart failure 0.688 N/a Calculated 
Abbreviations: MRA = Mineralocorticoid receptor antagonist (Aldosterone antagonist); ACEi = Angiotensin converting 
enzyme inhibitor; AHF = Acute heart failure; ARB = Angiotensin receptor antagonist; BNP = B-type natriuretic peptide; CV = 
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Cardiovascular; HF = Heart failure; HFSN = Heart failure specialist nurse; LVSD = Left ventricular systolic dysfunction; NP = 
Natriuretic peptide.*The included factors were: systolic blood pressure; haemoglobin; NHYA class; urea; creatinine; serum 
sodium; serum potassium; age; gender; previous chronic obstructive pulmonary disease; previous myocardial infarction; 
previous ischemic heart disease; previous vascular disease. 
 
Table 2 Hazard ratios of gold standard interventions for left ventricular systolic dysfunction. Results of 
meta-analysis. 95% confidence intervals in parenthesis.  
LVSD medication Cardiovascular mortality Readmission due to worsened HF 
ACEi/ARBs versus placebo 0.91 [0.83, 1.00] 0.80 [0.75, 0.86] 
BBs versus placebo 0.75 [0.61, 0.93] 0.76 [0.66, 0.87] 
AA/MRAs versus placebo 0.80 [0.65, 0.98] 0.65 [0.54, 0.78] 
Abbreviations: AA = Aldosterone antagonist / mineralocorticoid receptor antagonist; ACEi = 
Angiotensin converting enzyme inhibitor; ARB = Angiotensin receptor blocker; BB = Beta blocker 
Table 3 Life-years, QALYs and disaggregated per patient costs by strategy 
Strategy Life years QALYs 
Diag-
nostic 
work-up 
Index 
admission 
Re-
admissions 
Drugs and 
visits 
Total 
patient 
cost 
SCI and no SPO 3.154 2.212 £36 £2,027 £316 £274 £2,654 
NP and no SPO 3.159 2.216 £69 £2,035 £308 £285 £2,698 
SCI and SPO 3.178 2.229 £36 £2,047 £305 £315 £2,703 
NP and SPO 3.188 2.236 £69 £2,060 £296 £334 £2,759 
Abbreviations: NP = Natriuretic peptide test; SCI = standard clinical investigations; SPO = Specialist 
outreach 
 
